gentamicin has been researched along with oritavancin in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Houlihan, HH; Mercier, RC; Rybak, MJ | 1 |
| Andrews, J; Fraise, AP; Wise, R | 1 |
| Booker, B; Hoban, DJ; Karlowsky, JA; Laing, N; Zelenitsky, SA; Zhanel, GG | 1 |
| Aeschlimann, JR; Hershberger, E; Moldovan, T; Rybak, MJ | 1 |
| Aeschlimann, JR; Allen, GP; Hershberger, E; Rybak, MJ | 1 |
| Carbon, C; Fantin, B; Garry, L; Lefort, A; Saleh-Mghir, A | 1 |
| Blanco, MT; Gómez-García, AC; Hurtado, C; Morán, FJ; Pérez-Giraldo, C; Sánchez-Silos, RM | 1 |
| Seral, C; Tulkens, PM; Van Bambeke, F | 1 |
| Arhin, FF; Belley, A; McKay, GA; Moeck, G; Neesham-Grenon, E; Parr, TR | 1 |
| Becker, K; Denis, O; Garcia, LG; Kahl, BC; Lemaire, S; Proctor, RA; Tulkens, PM; Van Bambeke, F | 1 |
| Karau, MJ; Patel, R; Raval, YS; Yan, Q | 1 |
11 other study(ies) available for gentamicin and oritavancin
| Article | Year |
|---|---|
Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enterococcus faecium; Evaluation Studies as Topic; Gentamicins; Glycopeptides; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Rifampin; Staphylococcus aureus; Vancomycin | 1997 |
Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Topics: Ampicillin; Anti-Bacterial Agents; Enterococcus; Enterococcus faecalis; Enterococcus faecium; Gentamicins; Glycopeptides; Gram-Positive Bacteria; Lipoglycopeptides; Microbial Sensitivity Tests; Teicoplanin; Vancomycin | 1997 |
Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model.
Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Drug Synergism; Enterococcus faecium; Gentamicins; Glycopeptides; Lipoglycopeptides; Microbial Sensitivity Tests; Models, Biological; Time Factors; Vancomycin | 1999 |
Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by
Topics: Ampicillin; Anti-Bacterial Agents; Antibiotics, Antitubercular; Drug Therapy, Combination; Fluoroquinolones; Gentamicins; Glycopeptides; Lipoglycopeptides; Microbial Sensitivity Tests; Naphthyridines; Rifampin; Staphylococcus aureus; Sulbactam; Teicoplanin; Time Factors; Vancomycin; Virginiamycin | 1999 |
Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
Topics: Anti-Bacterial Agents; Colony-Forming Units Assay; Drug Therapy, Combination; Gentamicins; Glycopeptides; Lipoglycopeptides; Microbial Sensitivity Tests; Models, Biological; Staphylococcus aureus; Time Factors; Vancomycin; Vancomycin Resistance | 2000 |
Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Therapy, Combination; Endocarditis, Bacterial; Enterococcus faecalis; Female; Gentamicins; Glycopeptides; Lipoglycopeptides; Microbial Sensitivity Tests; Rabbits; Selection, Genetic; Vancomycin Resistance | 2000 |
Resistance to vancomycin, LY333328, ciprofloxacin and trovafloxacin of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) with and without high-level resistance to streptomycin and gentamicin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Gentamicins; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Incidence; Lipoglycopeptides; Microbial Sensitivity Tests; Naphthyridines; Spain; Streptomycin; Vancomycin | 2001 |
Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Fluoroquinolones; Gentamicins; Glycopeptides; Lipoglycopeptides; Lymphoma, Large B-Cell, Diffuse; Macrophages; Mice; Microbial Sensitivity Tests; Microscopy, Electron; Moxifloxacin; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Tumor Cells, Cultured | 2003 |
Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Drug Synergism; Fluoroquinolones; Gentamicins; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Oxazolidinones; Polysorbates; Quinolines; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Surface-Active Agents; Vancomycin Resistance | 2008 |
Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections.
Topics: Anti-Bacterial Agents; Cell Line; Daptomycin; Gentamicins; Glycopeptides; Hemin; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Monocytes; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Vancomycin; Vitamin K 3 | 2012 |
Evaluation of Oritavancin Combinations with Rifampin, Gentamicin, or Linezolid against Prosthetic Joint Infection-Associated Methicillin-Resistant Staphylococcus aureus Biofilms by Time-Kill Assays.
Topics: Biofilms; Gentamicins; Linezolid; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Rifampin | 2018 |